PP134 The Impact Of Pan-Canadian Oncology Drug Review Coming Under The Remit Of The Canadian Agency For Drugs And Technologies In Health – Three Year Update
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Technology Assessment in Health Care"
DOI: 10.1017/s0266462318002684
Abstract: Introduction: The pan-Canadian Oncology Drug Review (pCODR) was established in 2010 to bring consistent oncology drug assessments across Canadian provinces/territories. In April 2014, pCODR was transferred to the Canadian Agency for Drugs and Technologies in… read more here.
Keywords: oncology drug; pcodr; year; percent ... See more keywords
Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development
Sign Up to like & getrecommendations! Published in 2019 at "Clinical and Translational Science"
DOI: 10.1111/cts.12703
Abstract: Oncology drug development is among the most challenging of any therapeutic area, with first‐in‐human trials expected to deliver information on both safety and activity. Until recently, therapeutic approaches in oncology focused on cytotoxic chemotherapy agents,… read more here.
Keywords: drug development; oncology; oncology drug; healthy volunteers ... See more keywords
Oncology Drug Shortages—What We Have Versus What We Expect to Have? A Critical Scenario of Pakistan
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pharmacy Technology"
DOI: 10.1177/8755122518810853
Abstract: Drug shortages in tertiary care hospitals always limit the health system’s ability to provide quality care to the patients. Immediately following the existing shortage of 5 different oncology drugs in Pakistan, numerous patients are finding… read more here.
Keywords: oncology drug; shortages versus; drug shortages; care ... See more keywords
Non-oncology drug (meticrane) shows anti-cancer ability in synergy with epigenetic inhibitors and appears to be involved passively in targeting cancer cells
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1157366
Abstract: Emerging evidence suggests that chemotherapeutic agents and targeted anticancer drugs have serious side effects on the healthy cells/tissues of the patient. To overcome this, the use of non-oncology drugs as potential cancer therapies has been… read more here.
Keywords: oncology; oncology drug; anti cancer; meticrane ... See more keywords